Best of ASH Conference Coverage

Evaluating Pirtobrutinib in Patients with Previously Treated Mantle Cell Lymphoma

Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed promising efficacy in patients with previously treated mantle cell lymphoma (MCL), according to updated data from the phase I/II BRUIN study, presented at the 2021...

Curated Journal reading List

Advertisement
Advertisement

Expert Interviews